Related Experiment Video

Updated: Jul 11, 2026

Transcutaneous Microcirculatory Imaging in Preterm Neonates
06:27

Transcutaneous Microcirculatory Imaging in Preterm Neonates

Published on: December 31, 2015

Vancomycin pharmacokinetics in preterm infants

Jose Kleber Kobol Machado1, Rubens Feferbaum, Celia Etsuco Kobayashi

  • 1University of Sao Paulo, Medical School, Sao Paulo, SP, Brazil.

Clinics (Sao Paulo, Brazil)
|September 8, 2007
PubMed

Insights

Vancomycin trough plasma concentration in preterm infants is influenced by pharmacokinetic factors. These factors, including volume of distribution and half-life, vary with postconceptional and postnatal age.

Area of Science:

  • Pharmacology
  • Neonatal Medicine
  • Clinical Pharmacokinetics

Background:

  • Vancomycin is crucial for treating infections in preterm infants.
  • Understanding vancomycin pharmacokinetics is essential for optimizing therapeutic efficacy and minimizing toxicity in this vulnerable population.
  • Postconceptional age (PCA) and postnatal age (PNA) significantly impact drug disposition in neonates.

Purpose of the Study:

  • To evaluate the kinetic disposition of vancomycin in preterm infants.
  • To determine the relationship between apparent volume of distribution, biological half-life, total body clearance, and vancomycin trough plasma concentration.
  • To assess the influence of PCA and PNA on these pharmacokinetic parameters.

Main Methods:

  • A study involving 25 preterm infants divided into two groups based on PCA and PNA.
  • Analysis of pharmacokinetic parameters including apparent volume of distribution, biological half-life, and total body clearance.
  • Multiple linear regression analysis to correlate pharmacokinetic parameters with vancomycin trough plasma concentration.

Main Results:

  • Apparent volume of distribution was significantly higher in the younger PCA group (group 1) compared to the older PCA group (group 2).
  • A strong linear correlation was observed between vancomycin trough plasma concentration and apparent volume of distribution/biological half-life in group 1 (r=0.85).
  • A strong linear correlation was observed between vancomycin trough plasma concentration and total body clearance in group 2 (r=0.91).

Conclusions:

  • Vancomycin trough plasma concentration is dependent on pharmacokinetic parameters.
  • The relationship between pharmacokinetic parameters and vancomycin trough concentration varies with PCA and PNA in preterm infants.
  • These findings highlight the importance of age-specific pharmacokinetic monitoring for vancomycin therapy in preterm neonates.
Abstract

More Related Videos

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Estimation of k and VD of Aminoglycosides01:20

Estimation of k and VD of Aminoglycosides

Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...